Aura Biosciences, Inc. (AURA)Healthcare | Biotechnology | Boston, United States | NasdaqGM
7.29 USD
+0.23
(3.258%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.29 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:34 p.m. EDT
Despite the strong buy analyst consensus and a golden cross technical signal, Aura Biosciences is a dangerous long-term play; it is a small-cap biotech with a negative forward P/E, negative free cash flow, and a recent year of net insider selling. The options flow confirms this caution, with heavy put buying at lows acting as a floor but no real momentum driving a short-term bullish thesis, resulting in a speculative hold at best rather than a clear buy. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.093491 |
| AutoETS | 0.095881 |
| AutoARIMA | 0.102828 |
| AutoTheta | 0.104947 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 11.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.276 |
| Excess Kurtosis | -1.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.692 |
| Market Cap | 467,656,896 |
| Forward P/E | -3.59 |
| Beta | 0.35 |
| Website | https://www.aurabiosciences.com |
As of April 18, 2026, 11:34 p.m. EDT: Speculators show no meaningful bullish positioning. While there is limited open interest in calls, the primary activity involves significant volume (980 contracts) in OTM puts (5T strikes) expiring in July, which indicates a hedge or bearish speculation bet on downside rather than upside conviction. The implied volatility for these puts is low (0.25%), suggesting the market is pricing in low downside risk at these strikes, whereas ATM call IV is elevated (10.22%), reflecting uncertainty but a lack of directional gamma exposure for supports.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.30879712 |
| Address1 | 80 Guest Street |
| Address2 | 5th Floor |
| All Time High | 26.16 |
| All Time Low | 4.345 |
| Ask | 9.06 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 355,310 |
| Average Daily Volume3 Month | 260,222 |
| Average Volume | 260,222 |
| Average Volume10Days | 355,310 |
| Beta | 0.351 |
| Bid | 5.34 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 2.153 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.29 |
| Current Ratio | 8.146 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.48 |
| Day Low | 7.055 |
| Debt To Equity | 12.692 |
| Display Name | Aura Biosciences |
| Earnings Timestamp | 1,774,873,800 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -111,662,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.052 |
| Enterprise Value | 340,792,896 |
| Eps Forward | -2.03 |
| Eps Trailing Twelve Months | -1.76 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.1674 |
| Fifty Day Average Change | 1.1226001 |
| Fifty Day Average Change Percent | 0.18202162 |
| Fifty Two Week Change Percent | 30.879711 |
| Fifty Two Week High | 7.48 |
| Fifty Two Week High Change | -0.19000006 |
| Fifty Two Week High Change Percent | -0.025401076 |
| Fifty Two Week Low | 4.345 |
| Fifty Two Week Low Change | 2.9450002 |
| Fifty Two Week Low Change Percent | 0.67779064 |
| Fifty Two Week Range | 4.345 - 7.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,635,514,200,000 |
| Float Shares | 37,112,329 |
| Forward Eps | -2.03 |
| Forward P E | -3.591133 |
| Free Cashflow | -48,088,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 113 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.020299999 |
| Held Percent Institutions | 0.84600997 |
| Implied Shares Outstanding | 64,150,468 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts. |
| Long Name | Aura Biosciences, Inc. |
| Market | us_market |
| Market Cap | 467,656,896 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_100249028 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -106,191,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 468,298,416 |
| Number Of Analyst Opinions | 5 |
| Open | 7.19 |
| Operating Cashflow | -84,742,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8864 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.29 |
| Post Market Time | 1,776,456,604 |
| Previous Close | 7.06 |
| Price Hint | 2 |
| Price To Book | 3.385973 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.846 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | 0.23 |
| Regular Market Change Percent | 3.25779 |
| Regular Market Day High | 7.48 |
| Regular Market Day Low | 7.055 |
| Regular Market Day Range | 7.055 - 7.48 |
| Regular Market Open | 7.19 |
| Regular Market Previous Close | 7.06 |
| Regular Market Price | 7.29 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 427,553 |
| Return On Assets | -0.40061 |
| Return On Equity | -0.73517996 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,150,468 |
| Shares Percent Shares Out | 0.040799998 |
| Shares Short | 2,615,841 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,249,277 |
| Short Name | Aura Biosciences, Inc. |
| Short Percent Of Float | 0.0463 |
| Short Ratio | 8.96 |
| Source Interval | 15 |
| State | MA |
| Symbol | AURA |
| Target High Price | 26.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 20.4 |
| Target Median Price | 22.0 |
| Total Cash | 144,240,992 |
| Total Cash Per Share | 2.248 |
| Total Debt | 17,377,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.76 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.12365 |
| Two Hundred Day Average Change | 1.1663499 |
| Two Hundred Day Average Change Percent | 0.19046645 |
| Type Disp | Equity |
| Volume | 427,553 |
| Website | https://www.aurabiosciences.com |
| Zip | 2,135 |